Neogen Chemicals: Zero Deviation in Preferential Issue Fund Utilization for Q1FY27
Neogen Chemicals reports zero deviation in the utilization of ₹161 crore raised via Preferential Issue for the quarter ended June 30, 2026. Funds were allocated to subsidiaries, working capital, and general corporate purposes, as confirmed by CRISIL Ratings Limited, the Monitoring Agency. The company has fully utilized the issue proceeds.
This is a routine regulatory filing confirming the proper utilization of previously raised funds, with no new financial events or significant business developments.
The announcement confirms no deviation in the utilization of funds raised through a preferential issue, which is a positive indicator of financial discipline and adherence to stated objectives.
Neogen Chemicals Limited has submitted its Statement of Deviation/Variation for the quarter ended June 30, 2026, concerning the utilization of funds raised through a Preferential Issue. The company confirms that there has been no deviation or variation in the utilization of the ₹161 crore raised.
The funds were allocated as follows: ₹100 crore for investment in wholly-owned subsidiaries Neogen Ionics Limited and Buli Chemicals India Private Limited, ₹21 crore for meeting working capital requirements, and ₹40 crore for general corporate purposes. The company has confirmed that the utilization of funds for general corporate purposes did not exceed 25% of the gross proceeds.
CRISIL Ratings Limited, appointed as the Monitoring Agency, has issued its final report for the quarter ended June 30, 2026. The report, reviewed by the Audit Committee on July 24, 2026, also indicates no deviation in the utilization of funds. The proceeds have been fully utilized as per the disclosures in the offer document.
What to do with a filing like this
Neogen Chemicals Limited filed this with the NSE as a statutory disclosure, categorised under equity fundraising. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Neogen Chemicals Limited. Read the original for the full detail.